7-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)-1,8-naphthyridin-2(1H)-one | 1309857-70-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)-1,8-naphthyridin-2(1H)-one
• CAS: 1309857-70-2
• 化学式: C₁₇H₂₂N₂O₄
• 分子量: 318.373
• InChiKey: GYWYANVNFNHPKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.63
• 重原子数：
  23.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  73.44
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  7-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)-1,8-naphthyridin-2(1H)-one 在 盐酸 、 甲醇 、 2-碘酰基苯甲酸 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 4-(7-oxo-7,8-dihydro-1,8-naphthyridin-2-yloxy)butanal
  参考文献：
  名称：

  Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder

  摘要：

  The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D-2 partial agonists is described. Our goal was to optimize the affinities for the D-2, 5-HT2A and 5-HT1A receptors, such that the D-2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D-2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.059
• 作为产物：
  描述：

  2,6-二氨基吡啶 在 吡啶 、 硫酸 、 氢氟酸 、 potassium tert-butylate 、 sodium nitrite 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 1.0h， 生成 7-(4-((tetrahydro-2H-pyran-2-yl)oxy)butoxy)-1,8-naphthyridin-2(1H)-one
  参考文献：
  名称：

  Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder

  摘要：

  The synthesis and structure-activity relationship (SAR) of a novel series of aryl piperazine napthyridinone D-2 partial agonists is described. Our goal was to optimize the affinities for the D-2, 5-HT2A and 5-HT1A receptors, such that the D-2/5-HT2A ratio was greater than 5 to ensure maximal occupancy of these receptors when the D-2 occupancy reached efficacious levels. This strategy led to identification of PF-00217830 (2) with robust inhibition of sLMA (MED = 0.3 mg/kg) and DOI-induced head twitches in rats (31% and 78% at 0.3 and 1 mg/kg) with no catalepsy observed at the highest dose tested (10 mg/kg). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.059